Brain aging clocks advance from global metrics to precision neural medicine

Brain aging clocks have graduated from simple global biomarkers to sophisticated multimodal instruments that capture regional heterogeneity and measure the pace of neural aging at cellular resolution. Unlike systemic aging clocks designed to predict general mortality risk, brain-specific clocks address a critical biological reality: different tissues age at different rates, and accelerated brain aging is a direct risk factor for neurodegeneration and cognitive decline. Researchers now integrate structural neuroimaging, DNA methylation-based epigenetic signatures, and emerging plasma biomarkers—neurofilament light, GFAP, phosphorylated tau—to construct multidimensional profiles of neurobiological state. The underlying mechanisms span cellular senescence, vascular dysfunction, blood-brain barrier breakdown, mitochondrial decline, and protein aggregation pathology. For the longevity-curious reader, this represents the leap toward true precision medicine: the goal is no longer predicting average brain aging, but detecting individual acceleration and deploying targeted senotherapeutics before neurodegeneration becomes clinically manifest, while accounting for socioeconomic and geographic disparities that shape these trajectories.